ProQR Therapeutics (PRQR) Cash & Equivalents (2021 - 2024)
Historic Cash & Equivalents for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $159.7 million.
- ProQR Therapeutics' Cash & Equivalents rose 2477.45% to $159.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $159.7 million, marking a year-over-year increase of 2477.45%. This contributed to the annual value of $161.7 million for FY2024, which is 2570.42% up from last year.
- Per ProQR Therapeutics' latest filing, its Cash & Equivalents stood at $159.7 million for Q4 2024, which was up 2477.45% from $128.0 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Cash & Equivalents registered a high of $214.5 million during Q4 2021, and its lowest value of $91.3 million during Q2 2021.
- In the last 4 years, ProQR Therapeutics' Cash & Equivalents had a median value of $149.2 million in 2023 and averaged $149.5 million.
- Within the past 5 years, the most significant YoY rise in ProQR Therapeutics' Cash & Equivalents was 11909.53% (2022), while the steepest drop was 5492.59% (2022).
- Quarter analysis of 4 years shows ProQR Therapeutics' Cash & Equivalents stood at $214.5 million in 2021, then crashed by 54.93% to $96.7 million in 2022, then skyrocketed by 32.33% to $128.0 million in 2023, then grew by 24.77% to $159.7 million in 2024.
- Its Cash & Equivalents stands at $159.7 million for Q4 2024, versus $128.0 million for Q4 2023 and $131.2 million for Q3 2023.